Oxycodon Comp. Abz

Active Ingredient:: Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate
Origin:: EU

Oxycodon Comp. Abz (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxycodon Comp. Abz, is an opioid analgesic presented as a solid oral dosage form for oral use. It treats moderate to severe pain in adult patients when other analgesics are insufficient. Naloxone Hydrochloride Dihydrate, the secondary active ingredient, is included to reduce opioid‑induced constipation and abuse potential.

GNH India supplies Oxycodon Comp. Abz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Abz-Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodon Comp. Abz combines opioid analgesia with an abuse‑deterrent component and is used in the management of pain conditions that require strong opioid therapy.

Acute postoperative pain: provides rapid relief following surgery.
Cancer‑related pain: helps control persistent pain associated with malignant disease.
Severe chronic non‑cancer pain: used when other analgesics fail to provide adequate relief.

How It Works

Oxycodone binds to μ‑opioid receptors in the central nervous system, producing analgesia by inhibiting pain signal transmission. Naloxone, a μ‑opioid antagonist with low oral bioavailability, remains largely inactive when taken orally but blocks opioid receptors if the formulation is tampered with, thereby reducing the risk of misuse and mitigating opioid‑induced constipation.

Side Effects

Adverse reactions may occur with any opioid‑containing product and should be monitored throughout therapy.

Common Side Effects

Nausea: mild to moderate upset stomach.
Constipation: reduced bowel motility.
Dizziness: light‑headed sensation.
Somnolence: increased sleepiness.
Dry mouth: reduced salivation.
Pruritus: mild itching.

Serious or Rare Side Effects

Respiratory depression: slowed breathing, potentially life‑threatening.
Severe hypotension: marked drop in blood pressure.
Acute opioid intoxication: confusion, extreme sedation.
Allergic reactions: rash, swelling, anaphylaxis.
Seizures: rare neurologic events.
Dependence or withdrawal: signs of physical dependence on cessation.

Precautions & Warnings

When prescribing Oxycodon Comp. Abz, clinicians should evaluate patient history and monitor for adverse events.

Assess renal and hepatic function: adjust use in impairment.
Evaluate respiratory status: avoid in severe respiratory depression.
Review concomitant CNS depressants: increased sedation risk.
Monitor for signs of abuse: educate patients on proper use.
Pregnancy and lactation: use only if benefits outweigh risks.
Store below 25°C: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Oxycodon Comp. Abz can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

Benzodiazepines: heightened risk of respiratory depression.
CNS depressants: additive sedation and hypotension.
MAO inhibitors: potential for severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

CYP3A4 inhibitors (e.g., erythromycin): may increase oxycodone levels.
CYP3A4 inducers (e.g., rifampicin): may reduce analgesic effect.
Antihistamines: may enhance drowsiness.
Diuretics: may exacerbate hypotension.
Antidepressants (SSRIs/SNRIs): monitor for serotonin syndrome.

Frequently Asked Questions

Oxycodon Comp. Abz is an oral combination of oxycodone and naloxone indicated for the management of moderate to severe pain, including postoperative pain, cancer‑related pain, and chronic non‑cancer pain when other analgesics are insufficient.

Oxycodone activates μ‑opioid receptors in the brain and spinal cord, which reduces the perception of pain by inhibiting the transmission of nociceptive signals. The naloxone component remains inactive when taken as prescribed but blocks opioid receptors if the tablet is altered, helping to deter misuse.

The specific dose of Oxycodon Comp. Abz is determined by the prescribing clinician based on the severity of pain, patient tolerance, and prior opioid exposure. Dosage adjustments are made according to individual response and safety considerations.

Use during pregnancy or lactation is only recommended when the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case carefully and consider alternative therapies when possible.

To request Oxycodon Comp. Abz, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Compared with single‑component opioids, the oxycodone‑naloxone combination adds an abuse‑deterrent feature and reduces opioid‑induced constipation. Efficacy for pain relief is similar to other strong opioids, while the naloxone component helps mitigate some gastrointestinal side effects when taken as directed.

Store the product at or below 25 °C in its original packaging, protected from moisture and direct light. Do not expose the tablets to excessive heat or humidity to maintain potency and stability.

The medication is taken orally, usually with water. It may be administered with or without food, but consistent intake with respect to meals helps maintain stable drug levels. Patients should follow the prescribing clinician’s instructions regarding timing and frequency.

The most serious risks include respiratory depression, severe hypotension, opioid dependence, and rare allergic reactions such as anaphylaxis. Immediate medical attention is required if breathing becomes shallow, blood pressure drops markedly, or signs of a severe allergic response appear.

Individuals with known hypersensitivity to oxycodone, naloxone, or any excipients, as well as patients with severe respiratory insufficiency, acute or severe asthma, or untreated obstructive sleep apnea, should avoid this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.